Monday, 28 September 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Earnings Call

Rossari Biotech Earnings Call: Key Takeaways

Rossari Biotech achieved highest-ever Q4 revenue and EBITDA in FY26, driven by 15% volume-led annual revenue growth. Focus is shifting toward high-margin pharma and oil & gas segments.

Why this was an Alfa AlertNot a filter event. Results and guidance are in line with management's stated trajectory, not materially exceeding a specific prior range.
Highlights
Revenue growth15% annual growth, 18% Q4 growth.
MarginsB2B margins at 14%; group margins 12-13%.
Order bookGood pipeline of projects across sales teams.
Demand visibilityRobust orders; agro dependent on El Nino.
Management confidenceBullish on 15%+ growth for FY27.

Growth

FY26 revenue grew 15% to ₹2,396.4cr; Q4 revenue up 18% YoY to ₹684.9cr. EBITDA grew 8% YoY.

Outlook

Guided for minimum 15% revenue growth in FY27; EBITDA margins 12-13%; ₹50-75cr CAPEX; target debt-free in 18 months.

Risks

Geopolitical volatility in Middle East impacting raw material costs (25-30% spikes) and supply chain logistics.

Source

Earnings Call filed with NSE, NSE: ROSSARI. Summary written with AI assistance from the document.

Read the document ↗

Rossari Biotech Ltd: key numbers

Share price
₹444.20
Market cap
₹2,461 Cr
Revenue (annual)
₹2,396 Cr
Net profit (annual)
₹149.2 Cr
P/E (TTM)
16.3×Sector 37.5×
Promoter holding
68.14%-0.01% QoQ
FII holding
2.03%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Rossari Biotech Ltd

All →